-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Overcoming Post-transplant Relapse: How to Win the Battle Royale

Program: Education Program
Hematology Disease Topics & Pathways:
Treatment Considerations, Biological therapies, Transplantation (Allogeneic and Autologous)
Sunday, December 8, 2024: 9:30 AM-10:45 AM
Room 6CF (San Diego Convention Center)

Description:
Over the last few decades, significant progress in reducing infectious and immune-related complications of allogeneic hematopoietic cell transplantation have improved the feasibility and overall outcome of this complex procedure. Still, in patients patients transplanted for malignant diseases, reappearance of the original cancer, or relapse, continue to represent a crucial clinical issue. This educational session will present current knowledge on the biology of relapse, on how to tailor the transplant protocol to reduce its incidence, and on the use of novel drugs to prevent or treat recurrence.

Dr. Luca Vago will outline available evidence on the dynamic changes occurring in cancer cells and the patient immune system upon allogeneic hematopoietic cell transplantation, with a particular focus on how key aspects of the transplant such as donor choice and use of specific drugs impact on disease evolution, and on how state-of-the-art profiling of relapsed disease can help selecting appropriate countermeasures.

Dr. Ito's session begins by highlighting the current evidence of maintenance therapy for post-transplant relapse prevention, including targeted therapies, hypomethylating agents, venetoclax, and immunotherapies. The talk then shifts the focus to the role of relapse monitoring, emphasizing the importance of measurable residual disease and donor chimerism. Finally, the session will review the salvage therapies for overt relapse, including donor lymphocyte infusion, second allogeneic stem cell transplantation, and selected agents under investigation.

Dr. Pierini will speak on novel conditioning and prophylaxis regimens for relapse prevention.

Chair:
Luca Vago, MD, PhD, IRCCS Ospedale San Raffaele
Disclosures:
Vago: GEN-DX B.V., Utrecht, The Netherlands: Patents & Royalties.
Over the last few decades, significant progress in reducing infectious and immune-related complications of allogeneic hematopoietic cell transplantation have improved the feasibility and overall outcome of this complex procedure. Still, in patients patients transplanted for malignant diseases, reappearance of the original cancer, or relapse, continue to represent a crucial clinical issue. This educational session will present current knowledge on the biology of relapse, on how to tailor the transplant protocol to reduce its incidence, and on the use of novel drugs to prevent or treat recurrence.

Dr. Luca Vago will outline available evidence on the dynamic changes occurring in cancer cells and the patient immune system upon allogeneic hematopoietic cell transplantation, with a particular focus on how key aspects of the transplant such as donor choice and use of specific drugs impact on disease evolution, and on how state-of-the-art profiling of relapsed disease can help selecting appropriate countermeasures.

Dr. Ito's session begins by highlighting the current evidence of maintenance therapy for post-transplant relapse prevention, including targeted therapies, hypomethylating agents, venetoclax, and immunotherapies. The talk then shifts the focus to the role of relapse monitoring, emphasizing the importance of measurable residual disease and donor chimerism. Finally, the session will review the salvage therapies for overt relapse, including donor lymphocyte infusion, second allogeneic stem cell transplantation, and selected agents under investigation.

Dr. Pierini will speak on novel conditioning and prophylaxis regimens for relapse prevention.

Luca Vago, MD, PhD

IRCCS Ospedale San Raffaele, Milano, Italy

Antonio Pierini, MD, PhD

University of Perugia, Perugia, Italy; Department of Medicine and Surgery, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy

Sawa Ito, MD, PhD

Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA

See more of: Education Program